Weight Loss, Insomnia, and Blinking on Stimulant Therapy
A 7-year-old boy with ADHD combined presentation, diagnosed at age 6, has taken extended-release methylphenidate for four months: 18 mg for two months, then 36 mg. Teacher ratings improved markedly, and reading fluency gains are documented. His mother reports that he now takes 70 minutes to fall asleep, has stopped eating lunch at school, and has lost 2.4 kg, from 24.1 kg to 21.7 kg. Evening irritability has increased, with crying over small frustrations, and for one month he has had frequent eye blinking he cannot suppress. Blood pressure and heart rate are normal. Insurance covers only methylphenidate ER and guanfacine ER; amphetamine requires prior authorization with documented failure. The father has generalized anxiety disorder. The school calls weekly about 'defiance' during homework.
1. Sort this presentation into likely stimulant effects, likely comorbid or developmental problems, and findings that need separate evaluation. Justify each assignment.
Read the worked answer
Likely stimulant effects
- Appetite and weight: a 10% weight loss with lunch refusal is a recognizable dose-related effect, not a separate GI disorder, given the temporal link to the dose increase and normal examination.
- Sleep-onset delay: 70 minutes is typical of stimulant effects; duration of action and timing of dose are the usual levers.
- Blinking: tics emerge in a minority of stimulant-treated children, are often transient, and are more likely with a family history of tics. A new, simple motor tic in this context does not require urgent neurology referral.
- Evening irritability: the timing suggests rebound as the dose wears off, though anxiety or family stress could contribute.
Comorbid or developmental
- Homework 'defiance': with working memory and processing-speed weaknesses, task demands exceeding capacity commonly look like oppositionality. This is an instructional mismatch until proven otherwise; it is not evidence of ODD.
Needs separate evaluation
- Persistent weight loss despite intake optimization, or vomiting and diarrhea.
- Tics that become complex, impairing, or persist after dose reduction.
- Anxiety symptoms that are independent of dose timing, given paternal history. Screen with a validated instrument before treating.
2. Build a management plan that preserves the documented academic benefit under this formulary, including specific numbers, timing, and monitoring.
Read the worked answer
Do not abandon what is working; re-engineer it.
- Dose and timing. Step down to methylphenidate ER 27 mg given after a full breakfast (food taken first, dose taken after) rather than before. This preserves a therapeutic level during school while reducing peak anorexia and improving sleep onset. If 27 mg loses efficacy, consider splitting, or a small immediate-release dose in the morning, before returning to 36 mg.
- Nutrition plan. Scheduled high-calorie, protein-rich snacks at 4 pm and bedtime, when appetite returns; a calorie-dense breakfast; a school note permitting a mid-morning snack. Target weight regain of about 100 to 200 g per month, with weigh-ins every 2 weeks until stable, plotted on the growth chart. If weight falls below the 5th percentile or continues to drop, reduce the stimulant further.
- Sleep. Fixed wake time, no screens after 8 pm, dose before 8 am, and a brief parent-set wind-down. If sleep onset remains over 45 minutes, use guanfacine ER 1 mg at bedtime, which is covered and simultaneously addresses tics, sleep, and residual ADHD; titrate to 2 mg with blood pressure and heart rate checks and counseling about sedation.
- Homework. Reduce volume, break tasks down, use a written checklist, and stop at a set time with teacher notification.
- Recheck in 4 weeks with teacher and parent rating scales, weight, sleep diary, and tic log.
3. What findings would make you reconsider the ADHD diagnosis or conclude that a co-occurring anxiety disorder is present?
Read the worked answer
Signals of an anxiety disorder rather than stimulant effect
- Irritability and crying that are not tied to dose timing, or that predate the medication.
- Somatic complaints (headache, stomachache), school refusal, separation distress, perfectionism, or excessive reassurance-seeking.
- Sleep difficulty driven by worry or checking rather than delayed sleep onset.
- An elevated score on a validated anxiety screen (for example SCARED, parent and child), plus impairment in a second setting.
Signals to revisit the ADHD diagnosis
- Symptoms fully explained by anxiety, trauma, a language disorder, or a learning disorder.
- Inattention without hyperactivity or impulsivity, with onset after age 12, or symptoms present in a single setting only.
- Minimal response to two adequate stimulant trials and to a non-stimulant, with no dose-related pattern.
What would not change the diagnosis: homework difficulty alone, or a single teacher report, especially when teacher ratings improved with treatment.
If anxiety is confirmed, treat it rather than escalating the stimulant: cognitive-behavioral therapy is first-line for this age, with an SSRI if impairing and therapy is insufficient. Reassess the medication once anxiety is addressed.